Novartis and Biofourmis’ deal to pair heart failure drug Entresto with the digital company’s BiovitalsHF platform for monitoring and managing patients is the latest sign that biopharmas are embracing digital technologies to help demonstrate value to payers.
Under the deal, announced Nov. 18, patients prescribed Entresto sacubitril/valsartan will receive Biofourmis’ Biovitals package, which includes a sensor and mobile app to capture and record data that are then linked with a patient’s electronic medical record (EMR). Biovitals will capture nearly two dozen different metrics to predict a patient’s likelihood of having a heart failure exacerbation, and provide software-based therapeutic recommendations to patients’ clinicians and care teams to enable early intervention.
Separately, Biofourmis announced Nov. 18 that it acquired Biovotion AG, bringing in house the clinical-grade sensor that will be deployed in the Novartis deal, and adding Biovotion’s toolbox of technologies to assess patient response in real time.
“We will be demonstrating to payers that Entresto drives better outcomes.”
The goal for Novartis and Biofourmis is to show that Entresto, when